ScinoPharm Taiwan 15th in 2025 CSR “Small Giants”

ScinoPharm Taiwan has been recognized as the 15th winner in the “Small Giants” category of CommonWealth Magazine’s 2025 Excellence in Corporate Social Responsibility Award, rising six places from 21st last year. This marks our second consecutive year on the list, and we are proud to be the only Taiwan-based pharmaceutical company included in 2025, highlighting our leadership in sustainability and corporate responsibility within the local pharmaceutical industry.

The CommonWealth CSR Award evaluates companies based on four key dimensions: Corporate Governance (G), Corporate Commitment (S), Social Engagement (S), and Environmental Sustainability (E). ScinoPharm Taiwan’s ranking reflects the company’s outstanding performance across these areas, demonstrating our long-standing dedication to ethical governance, environmental stewardship, and social impact. Specializing in high-barrier API and drug product development and manufacturing, ScinoPharm provides fully integrated solutions and continues to leverage its expertise to promote sustainable business practices and global health initiatives.

Looking ahead, ScinoPharm Taiwan will continue to build on its pharmaceutical expertise to deepen ESG strategies, working closely with employees, partners, and the wider community. We remain committed to advancing health and sustainability in tandem, embodying our brand spirit: “For every life. With every trust.”